Current Affairs Topics Archive
International Relations Economics Polity & Governance Environment & Ecology Science & Technology Internal Security Geography Social Issues Art & Culture Modern History

We now know why some people had severe blood clots after COVID shots

March 10, 2026 5 min read Science & Technology GS3 (Science & Technology)
On This Page ▼

What Happened

  • A landmark study published in the New England Journal of Medicine (February 2026) has provided the first clear molecular explanation for Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT) — a rare but severe clotting condition seen after some COVID-19 adenoviral vector vaccines
  • Researchers identified adenoviral protein VII (pVII) as the initial immune trigger — this viral protein closely resembles a region of human platelet factor 4 (PF4), a blood protein involved in clotting
  • In rare cases, a single specific mutation (K31E — a single amino acid change) in an antibody-producing cell causes the immune response to redirect from targeting pVII to mistakenly attacking PF4
  • The K31E mutation was detected in all VITT patient antibodies examined; when researchers reversed the mutation in lab-engineered antibodies, the dangerous clotting activity disappeared — proving the causal link
  • Only people who inherit a specific antibody gene variant (IGLV3-2102 or 03), found in up to 60% of the population, can develop VITT — though additional factors must align for the condition to manifest
  • The discovery enables vaccine developers to redesign adenoviral vector components to prevent VITT while preserving vaccine effectiveness

Static Topic Bridges

Adenoviral Vector Vaccines: Technology and Examples

Adenoviral vector vaccines use a modified, non-replicating adenovirus (a common cold virus) as a delivery vehicle to introduce genetic instructions for a target antigen into human cells. The adenovirus is engineered to carry the gene encoding the pathogen's antigen (e.g., SARS-CoV-2 spike protein), which the host cell then produces, triggering an immune response. This technology was used in several COVID-19 vaccines — notably the Oxford-AstraZeneca (ChAdOx1) vaccine and Johnson & Johnson's Janssen vaccine. The same platform underpins Ebola vaccines and has broader potential for HIV, malaria, and cancer immunotherapy.

  • AstraZeneca (ChAdOx1 nCoV-19 / Covishield): chimpanzee adenovirus vector; most widely used globally; deployed extensively in India through Serum Institute of India
  • Janssen (Ad26.COV2.S): human adenovirus 26 vector
  • Sputnik V: two-dose regimen using human adenoviruses 26 and 5
  • Adenoviral vectors vs mRNA vaccines: adenoviral vaccines are stable at standard refrigeration (2–8°C); mRNA vaccines require ultra-cold storage
  • Covishield was India's primary COVID-19 vaccine: administered to over 1 billion doses domestically

Connection to this news: VITT was documented specifically after adenoviral vector vaccines (especially ChAdOx1/Covishield and Janssen), not mRNA vaccines. The new study explains precisely why this platform — and not others — triggered this rare immune response.

VITT: Mechanism, Epidemiology, and Clinical Features

Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT) is a rare but potentially fatal condition characterised by thrombosis (blood clots in unusual locations, such as cerebral venous sinuses and splanchnic veins) combined with thrombocytopenia (low platelet count), typically occurring 4–28 days after adenoviral vector COVID-19 vaccination. It resembles heparin-induced thrombocytopenia (HIT) in its mechanism — antibodies against platelet factor 4 (PF4) activate platelets, paradoxically causing both clotting and low platelet counts. The incidence is estimated at approximately 1 in 100,000 to 1 in 250,000 vaccinations.

  • Incidence: approximately 1 in 100,000–250,000 doses of adenoviral COVID vaccines
  • Onset: 4–28 days post-vaccination
  • Common clot sites: cerebral venous sinuses, splanchnic veins (portal, hepatic, mesenteric) — atypical for common thrombosis
  • Key biomarker: anti-PF4 antibodies detectable in blood (similar to heparin-induced thrombocytopenia / HIT)
  • Treatment: Intravenous immunoglobulin (IVIG) and non-heparin anticoagulants (heparin worsens VITT)
  • VITT was a factor in several countries pausing or restricting ChAdOx1 vaccine use in younger age groups (2021–2022)

Connection to this news: The new study's molecular explanation (pVII → K31E mutation → anti-PF4 antibody) resolves the mechanism that had puzzled researchers since VITT first emerged in early 2021 and cast a shadow over adenoviral vaccines.

Molecular Mimicry and Autoimmune Responses

Molecular mimicry is a mechanism by which pathogens (or vaccine components) trigger autoimmune responses — the immune system, trained to recognise a foreign protein, mistakenly attacks a structurally similar host protein. This is considered a contributory mechanism in several autoimmune diseases, including rheumatic fever (streptococcal proteins mimicking cardiac tissue), Guillain-Barré syndrome, and type 1 diabetes. The newly described VITT mechanism is a precise, experimentally validated example of molecular mimicry: adenoviral protein VII (pVII) structurally resembles platelet factor 4 (PF4), and a single somatic mutation (K31E) is sufficient to redirect an anti-viral antibody into a dangerous anti-self antibody.

  • Molecular mimicry: foreign antigen resembles host protein → immune response misfires against self
  • Rheumatic fever classic example: Group A Streptococcus M-protein mimics cardiac myosin
  • VITT mechanism: pVII (adenoviral protein) → K31E mutation → anti-PF4 antibody (anti-self)
  • PF4 (Platelet Factor 4): a chemokine released by platelets; involved in blood clotting regulation
  • K31E mutation: single amino acid change (lysine → glutamate at position 31) in antibody variable region — switches positive charge to negative, enabling PF4 binding
  • IGLV3-21 gene variant: inherited antibody germline gene; carriers at genetic predisposition to VITT

Connection to this news: The identification of the K31E mutation as the switch from anti-viral to anti-self antibody provides a textbook molecular mimicry case study with direct vaccine safety implications — redesigning pVII to eliminate the PF4-resembling region could eliminate VITT risk.

Key Facts & Data

  • Study published: New England Journal of Medicine, February 2026
  • VITT trigger protein: adenoviral Protein VII (pVII) — resembles human Platelet Factor 4 (PF4)
  • Key mutation: K31E — single amino acid change (lysine → glutamate, position 31) in antibody variable region
  • Effect: redirects antibody from targeting pVII to targeting PF4 → platelet activation → clotting + low platelets
  • K31E confirmed in: all VITT patient antibodies examined; reversal of mutation abolishes dangerous activity
  • Genetic predisposition: IGLV3-2102 or 03 gene variant (present in up to 60% of population)
  • VITT incidence: ~1 in 100,000–250,000 adenoviral vaccine doses
  • Onset: 4–28 days post-vaccination; affects cerebral venous sinuses and splanchnic veins
  • Vaccines associated: ChAdOx1 (AstraZeneca/Covishield), Janssen (J&J), Sputnik V
  • Covishield doses administered in India: >1 billion (primary COVID-19 vaccine)
  • Treatment: IVIG + non-heparin anticoagulants (heparin contraindicated)
  • VITT can also occur after natural adenovirus infection (not just vaccination)